RFL लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 00:36):

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel...

Stats
आज की मात्रा	15 210.00
औसत मात्रा	23 488.00
बाजार मूल्य	40.57M
EPS	$0 ( 2024-03-12 )
अगली कमाई की तारीख	( $0 ) 2024-06-11
Last Dividend	$0.0200 ( 2009-12-18 )
Next Dividend	$0 ( N/A )
P/E	17.05
ATR14	$0.0220 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share
2024-04-04	Jonas Howard S	Sell	348 259	Class B Common Stock, par value $.01 per share
2024-03-21	Conkling William	Buy	15 473	Class B Common Stock, par value $.01 per share
2024-03-21	Polinsky David	Sell	2 300	Class B Common Stock, par value $.01 per share
2024-01-30	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share

INSIDER POWER
52.60
Last 99 transactions
Buy: 18 593 840 \| Sell: 14 829 947

Rafael Holdings Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Rafael Holdings Inc वित्तीय

Annual	2023
राजस्व:	$279 000
सकल लाभ:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2023
राजस्व:	$279 000
सकल लाभ:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2022
राजस्व:	$410 000
सकल लाभ:	$338 000 (82.44 %)
EPS:	$-6.31

FY	2021
राजस्व:	$3.97M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Rafael Holdings Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Rafael Holdings Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.90 - low (62.71%) | Divividend Growth Potential Score: 0.471 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2009-06-19
Last Dividend	$0.0200	2009-12-18
Next Dividend	$0	N/A
Payout Date	2009-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.0400	--
Avg. Dividend % Per Year	0.00%	--
Score	1.83	--
Div. Sustainability Score	4.90
Div.Growth Potential Score	0.471
Div. Directional Score	2.69	--

Next Divdend (Est)
(2024-10-14)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.83

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	7.77	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0201	1.200	9.33	10.00	[0 - 0.3]
returnOnEquityTTM	0.0213	1.500	-0.875	-1.312	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	23.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	22.86	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.19	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0160	-1.500	9.73	-10.00	[0 - 0.6]
interestCoverageTTM	-7.98	1.000	-4.07	-4.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
freeCashFlowPerShareTTM	1.775	2.00	9.11	10.00	[0 - 20]
debtEquityRatioTTM	0.0162	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.665	1.000	2.24	2.24	[0.2 - 0.8]
operatingProfitMarginTTM	-40.96	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.37	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00259	0.800	-3.32	-2.65	[0.5 - 2]
Total Score				4.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.85	1.000	8.20	0	[1 - 100]
returnOnEquityTTM	0.0213	2.50	-0.562	-1.312	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.775	2.00	9.41	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.313	1.500	-1.246	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-27.00	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.471

Rafael Holdings Inc

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.